The results from Phase 1 of the Troculeucel Clinical Trial demonstrated stable/improved outcomes in 90% of subjects, with no drug-related adverse ...
The Scientific Review Committee (SRC) charter is to review the safety data from the patients treated in the Phase I portion ...
The Fast Track designation accelerates troculeucel’s path to U.S. FDA submission for the treatment of patients with moderate Alzheimer’s ...
MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and ...
3d
Medical review of Phase 1 cohorts demonstrated no safety issuesData to be presented at the 10th Annual Innate Killer Summit, March 3-5 BOCA RATON, Fla, Feb. 12, 2025 (GLOBE NEWSWIRE) -- INmune Bio ...
Shares of Nkarta, Inc. (NASDAQ:NKTX – Get Free Report) have been assigned a consensus rating of “Buy” from the seven ...
So what: If you purchased Caribou securities during the Class Period you ... research activities associated with the allogeneic CAR-NK platform; (3) the foregoing was likely to have a significant ...
Aardvark Therapeutics plans a $100M IPO for metabolic treatments, targeting rare Prader-Willi syndrome with a potential ...
Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies. Read more to see why I rate FATE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback